Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Chronic lymphocytic leukemia (CLL) patients progressed early on ibrutinib often develop Richter transformation (RT) with a short survival of about 4 months. Preclinical studies suggest that programmed death 1 (PD-1) pathway is critical to inhibit immune surveillance in CLL. This phase 2 study was de...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood
Main Authors: Ding, Wei, LaPlant, Betsy R., Call, Timothy G., Parikh, Sameer A., Leis, Jose F., He, Rong, Shanafelt, Tait D., Sinha, Sutapa, Le-Rademacher, Jennifer, Feldman, Andrew L., Habermann, Thomas M., Witzig, Thomas E., Wiseman, Gregory A., Lin, Yi, Asmus, Erik, Nowakowski, Grzegorz S., Conte, Michael J., Bowen, Deborah A., Aitken, Casey N., Van Dyke, Daniel L., Greipp, Patricia T., Liu, Xin, Wu, Xiaosheng, Zhang, Henan, Secreto, Charla R., Tian, Shulan, Braggio, Esteban, Wellik, Linda E., Micallef, Ivana, Viswanatha, David S., Yan, Huihuang, Chanan-Khan, Asher A., Kay, Neil E., Dong, Haidong, Ansell, Stephen M.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2017
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5492091/
https://ncbi.nlm.nih.gov/pubmed/28424162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-02-765685
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki